聚焦创投圈投融资最新情报。 近日，国内低空智能机器人领军企业星逻智能宣布完成超亿元B+轮融资，本轮由苏州港航集团领投，临港前沿投资联合领投。此次融资将重点用于新 能源机器人产品化以及城市低空经济应用，进一步巩固星逻智能在无人机AI与新能源智能运维领域的领先地位。 作为中国低空经济领域的开拓者，星逻智能自2017年成立以来始终专注于无人机赋能技术的研发与商业化落地。公司推出的中国首台无人机机库、首 台无人机光伏巡检无人化系统等创新产品，已覆盖了全球超700个新能源场站，超40个区县低空应用，产品已应用于欧洲、东南亚、日本等地。 此次B+轮融资是继2024年6月的亿元级B轮融资后的又一里程碑，标志着星逻智能在新能源智维与低空城市领域的战略布局进入产业化阶段。 近日，蓝芯算力（深圳）科技有限公司（简称"蓝芯算力"）分别完成Pre-A轮及Pre-A+轮融资，获数亿元投资，由深创投和南山战新投联合领投、联想 创投、高伟达、金沙江联合、投控东海、银杏谷资本等共同跟投。据了解，蓝芯算力的Pre-A++轮也接近尾声，仍有数亿元的投资。本次融资主要用于 蓝芯算力服务器芯片的流片与量产、新一代服务器产品研发投入等。 自成立以来， ...

Group 1 - MSCI announced the inclusion of 30 new stocks and the removal of 61 stocks from its global equity index, with 5 A-shares from China being added [1] - The newly added A-shares include Chipone Technology, Baillie Gifford, Huatai Medical, Light Media, and Haisco Pharmaceutical, which all showed significant price increases on the trading day following the announcement [1][2] - Chipone Technology reported projected revenues of 2.322 billion yuan and a net profit of 601 million yuan for 2024, focusing on AI application solutions [2] - Light Media, a leading player in the entertainment sector, aims to diversify its revenue by becoming an "IP creator and operator" following the success of its animated film "Nezha 2" [2] - Baillie Gifford, specializing in biopharmaceuticals, expects revenues of 5.823 billion yuan in 2024, marking a 936.31% increase year-on-year, with a net profit of 3.708 billion yuan [2] - Haisco Pharmaceutical has 14 commercialized products and new drugs in clinical trials, focusing on innovative drug development [3] - Huatai Medical is recognized as a leading company in domestic electrophysiology and vascular intervention, with new products approved for atrial fibrillation treatment [3] Group 2 - The adjustments made by MSCI will take effect after the market closes on May 30, indicating that stocks entering the MSCI China Index will also be included in the MSCI Global Standard Index series, attracting passive investment tracking [3]

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 近日， 科塞尔医疗科技（苏州）有限公司 宣布完成近亿元 B+轮融资，此轮融资由铁投巨石领投，苏高新金 控持续追加投资，园雍投资跟投，所筹资金主要用于核心产品研发、全球市场推广及产能扩建。 历次融资情况 技术平台与专利 ： 科塞尔医疗累计研发投入超 3 亿元， 构建了丰富技术平台，拥有近百人研发、工艺和 注册团队，取得国内外发明专利数百项，包括 PCT 专利近百项。 核心产品与应用领域 ： 其外周领域的创新产品腔 静脉滤器 成功注册并顺利商业化，是国内首个获准注册 的伞形长效滤器。 冠脉领域的球囊类产品获得中国 NMPA、美国 FDA、欧盟 CE、日本 PMDA、韩国 KFDA 等多国注册证书并进入国际主流市场。目前已有两个创新产品成功商业化。 市场表现 ：公司产品已在国内 2000 家医院使用，在海外 20 余个国家完成产品注册。 2017 年初 ：完成由达晨财智中国风险投资基金领投的数千万元 Pre - A 轮融资。 2018 年中 ：获得博远资本领投，达晨财智跟投的数千万元 A 轮融资。 2020 年底 ：完成由渶 ...

Core Viewpoint - The medical health industry faces significant uncertainties in 2024, yet outstanding companies like Guichuang Tongqiao have emerged successfully, achieving over 100 million yuan in net profit and turning profitable for the first time, demonstrating resilience in a challenging environment [1][24]. Company Performance - Guichuang Tongqiao reported a revenue of 782 million yuan in 2024, a substantial increase of 48.3% year-on-year, with a compound annual growth rate (CAGR) of 64% from 2021 to 2024 [9][12]. - The company achieved a net profit of 100.3 million yuan in 2024, marking its first annual profit, with a significant year-on-year growth of 1,663% when adjusted for non-IFRS measures [12][13]. - The revenue from neurovascular intervention products reached 529 million yuan, accounting for 67.7% of total revenue, with a year-on-year growth of 38.4% [9][12]. - The revenue from peripheral vascular intervention products surged by 74.5% to 252 million yuan, representing 32.3% of total revenue [9][12]. Market Dynamics - The high-value medical consumables market in China has grown from 104.6 billion yuan in 2018 to 156.1 billion yuan in 2023, with vascular intervention being the largest segment at 55.9 billion yuan in 2023, showing a year-on-year growth of 13.77% [4][5]. - The penetration rate of vascular intervention products in China remains low compared to developed countries, indicating significant growth potential in this segment [7][20]. Competitive Landscape - Guichuang Tongqiao has successfully navigated the challenges posed by centralized procurement policies, achieving rapid growth through effective product quality and sales capabilities [15][20]. - The company has participated in multiple rounds of centralized procurement, with 36 out of 47 approved products successfully selected [15][16]. - The competitive landscape is shifting towards a focus on innovation and operational efficiency, with leading players needing to excel in procurement, operational excellence, and continuous innovation [7][24]. International Expansion - Guichuang Tongqiao has expanded its overseas business, generating 22.58 million yuan in 2024, a year-on-year increase of 58.2%, with a CAGR of 87% over the past four years [20][21]. - The company plans to introduce 14 new products in 2025, targeting 11 countries and regions, with expectations of doubling overseas revenue by 2025 [21][22]. Future Outlook - The company is positioned for sustainable growth with a robust product pipeline, having received approvals for over 40 products since 2021, and plans for 17 additional products to be launched between 2025 and 2027 [22][23]. - Guichuang Tongqiao's valuation is expected to recover significantly, with potential inclusion in major stock indices, which could attract substantial capital inflows [25][26].